Inhalable Biologics Market Expecting Huge Demand
ID: #69360
Listed In : Advertising
Business Description
Inhalable Biologics Market size was valued at US$ 3,210.0 Million in 2023 and is projected to grow from US$ 3,710.4 million in 2024 to US$ 10,844.5 Million by 2031, exhibiting a CAGR of 16.56% during the forecast period.
Access Detailed Research @ https://www.kingsresearch.com/inhalable-biologics-market-1690
Recent Developments:
In January 2025
Ethris GmbH announced positive Phase 1 results for ETH47, an mRNA-based nasal therapy for uncontrolled asthma. ETH47 showed dose-dependent interferon lambda (IFNλ) expression, confirming target engagement with no serious adverse events. Ethris plans to begin a Phase 2a trial in Q2 2025 to assess ETH47’s effect on asthma symptoms after rhinovirus infection.
Business Hours
Monday : 09:00 - 17:00
Tuesday - Closed
Wednesday - Closed
Thursday - Closed
Friday - Closed
Saturday - Closed
Sunday - Closed
